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doi: 10.1016/j.arcmBackground and Aims. HTLV-I-transformed T cells secrete biologically active forms of
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF). In
addition, HTLV-I-transformed cells have a high capacity of adhesion to endothelial cells.
Methods. We measured the circulating endothelial progenitor cells (EPCs) and mature
endothelial cells (MECs) by flow cytometry in 27 HTLV-I carriers in comparison to 30
healthy, age- and gender-matched subjects. All subjects had HTLV-I positivity confirmed
by Western blot and/or polymerase chain reaction (PCR). The numbers of different
subpopulations of EPCs and MECSs were evaluated by four-color flow cytometry using
a panel of monoclonal antibodies. All reactions were done in duplicate to confirm
reproducibility of the results.
Results. The median age of all 27 HTLV-I carriers enrolled in this study was 45 years
(range: 27e65 years); 11 (41%) were male and 16 (59%) were female. The median age
of the 30 healthy subjects in the control group was 45.5 years (range: 20e63 years); 11
(36.6%) were male and 19 (63.4%) were female. The number of EPCs was significantly
higher in HTLV-I carriers (median 0.8288 cells/mL, range: 0.0920e3.3176 cells/mL) as
compared to control group (median 0.4905 cells/mL, range: 0.0000e1.5660 cells/mL)
( p 5 0.035). In contrast, the median of the MECs in the HTLV-I carriers was 0.6380
cells/mL (range: 0.0473e5.7618 cells/mL) and 0.4950 cells/mL (range: 0.0000e4.0896
cells/mL) in the control group, with no statistical difference ( p 5 0.697).
Conclusions. We demonstrated that EPCs, but not MECs, are increased in the peripheral
blood of HTLV-I carriers.
 2011 IMSS. Published by Elsevier Inc. Open access under the Elsevier OA license.
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Adult T-cell leukemia (ATLL) is an aggressive mature
T-cell lymphoproliferative disorder linked to the human
T-cell lymphotropic virus type 1 (HTLV-I). Usually it is
characterized by a monoclonal expansion of the trans-
formed CD4 T lymphocytes (1,2). The HTLV-I belongs to
the retroviridae family and is endemic in Japan, Caribbeanequests to: Abrah~ao Elias Hallack Neto, Avenida
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Open access unand South America (3). Recently it was demonstrated that
leukemic cells of the ATLL have a high potential to invade
several tissues from the organism by interacting with the
endothelium. The E-selectin adhesion molecule is the main
adherence mediator between ATLL cells and endothelial
cells. In fact, HTLV-I-transformed T-cells can secrete the
vascular endothelial growth factor (VEGF) and basic fibro-
blast growth factor (bFGF), both induced by transcriptional
activation of the Tax viral protein. VEGF is also able to
regulate the circulating endothelial progenitor cells (EPCs)
differentiation and tumor neovascularization (4e7).
However, few studies have been performed to evaluate
the role of angiogenesis in HTLV-I carriers. In this study,der the Elsevier OA license.
35Endothelial Cells in HTLV-I Carriersin order to better understand angiogenesis, the physiolog-
ical process involving the growth of new blood vessels from
pre-existing vessels, in HTLV-I carriers we performed MEC
and EPC quantification.Subjects and Methods
Patients
This prospective study enrolled 27 consecutive HTLV-I
asymptomatic carriers. There were 11 (41%) males and
16 (59%) females with a median age of 45 years (range:
27e65 years) who presented in the Department of Hema-
tology at the Clinical Hospital of Sao Paulo University
between February 2006 and February 2007. All subjects
had HTLV-I positivity confirmed by Western blot and/or
polymerase chain reaction (PCR). A control group of 30
healthy blood donors was also evaluated. There were 11
(36.6%) males and 19 (63.4%) females with a median
age of 45.5 years (range: 20e63 years). No female controls
were evaluated during the menstrual period. The study was
approved by the local Ethics Committee and informed
consent was obtained from all HTLV-I carriers and controls.
Blood Sampling
Venousblood samples (10mL)were collected in pyrogen-free
EDTA tubes.
Flow Cytometry
The numbers of different subpopulations of circulating endo-
thelial cells (CECs) were evaluated by four-color flow cytom-
etry using a panel ofmonoclonal antibodies. Peripheral blood
was prepared by lyse/wash method. Briefly, 1  106 cells of
whole peripheral blood were set in three different and prop-
erly identified tubes. One was used as control and added with
the following: 10 mL of the monoclonal antibody (MoAb)
anti-CD45/PC5 (Immunotech, Marseille, France), clone J33
diluted 1:10 and isotypes controls. In tube two, the cells were
labeled with 10 mL of the CD146/FITC-Serotec, clone
OJ79C, 10 mL of the CD34 class III/PE (DakoCytomation,
Carpinteria, CA), clone BIRMA-K3, 10 mL/1:10 of the
CD45/PC5 and 10 mL CD133/APC (Miltenyi Biotec,
Auburn, WA), clone 293C3. In the last tube, the cells were
labeled with 10 mL of the MoAb CD146/FITC (Serotec,
Oxford, South East England, UK), 20 mL of the CD62e/PE
(BD Bioscience, San Diego, CA), clone TEA2/1, 10 mL/
1:10 of the CD45/PC5 and 10 mL of the CD133/APC. All
tubes were incubated in the dark for 20 min and
subsequently red cell lyses was performed with 200 mL of
Dako lyse solution diluted 1:10 in deionized water.
Afterwards, all tubes were centrifuged at 1000  g for 3
min and washed twice with 200 mL of PBS-azide (0.1%).
Finally, cells were resuspended in 400 ml formaldehyde
(1%) and acquired in the FACSCalibur [Becton Dickinson(BD), San Jose, CA] using CellQuestPro software. The
performance of the flow cytometer was monitored with Cali-
brate microbeads (BD) reagent in the FACSComp software
(BD) and subsequently 100,000 events per tube were
acquired and analyzed in theCellQuestPro software.All reac-
tions were performed in duplicate to confirm reproducibility.
AllMoAbswere validatedwithHUV-EC-C (ATCCno. CRL-
1730, Manassas, VA) cells cultivated in 199/EBS medium
complemented with 10% fetal bovine serum, 100 U/ml peni-
cillin, and 100 mg/mL streptomycin in our laboratory.
Analyses of Endothelial Cells
We selected all living cells in a side scatter (SSC)/CD45
plot (R1). We then chose and delimited the region corre-
spondent to the CD45 negative and low SSC (R2). Subse-
quently, we looked for CD146, CD34, CD62e and CD133
expression in other 2D fluorescence plots from R2
(Figure 1). ECPs were considered as CD45/dim/CD146þ//
CD133þ/CD62e and MECs as CD45/dim/CD146þ/
CD62eþ//CD133 (8,9). The percentage of CECs was
determined as a percentage of the total events after exclu-
sion of debris. The absolute count of the cells was then
calculated by multiplying the %EPCs or %MCEs obtained
by flow cytometry by absolute white cell count provided by
the hematology analyzer.
Statistical Analysis
Statistical analysis was performed with the BioEstat 4.0
software using the Mann-Whitney nonparametric test for
a two-tailed probability with alpha level significance of 5%.Results
There was no statistical difference in median age between
asymptomatic HTLV-I carriers and healthy controls. The
median age of the 27 HTLV-I carriers enrolled in this study
was 45 years (range: 27e65 years); 11 (41%) were male
and 16 (59%) were female. The median age of the 30
healthy control subjects was 45.5 years (range: 20e63
years); 11 (36.6%) were male and 19 (63.4%) were female.
The median leukocyte count of the HTLV-I carriers was
6.8  109/L (4.0  109/L to 14  109/L) and 6.2  109/L
(4.0  109/L to 10.6  109/L) in the control group.
No significant statistical difference was found between
the results obtained in duplicate reactions. We found that
the number of EPCs was significantly higher in HTLV-I
carriers (median 0.8288 cells/mL, range: 0.0920e3.3176
cells/mL) as compared to control group (median 0.4905
cells/mL, range: 0.0000e1.5660 cells/mL) ( p 5 0.035)
(Table 1). The median of the MECs in the HTLV-I carriers
was 0.6380 cells/mL (range: 0.0473e5.7618 cells/mL) and
0.4950 cells/mL (range: 0.00004.0896 cells/mL) in the
control group ( p 5 0.697).
Figure 1. EPC and MEC flow cytometry analysis in HTLV-I carriers (AeC) and in healthy subjects (DeE). (A) Gating used to exclude hematopoietic cells
expressing CD45 antigen after exclusion of platelets, cells death and debris. (B) CD45-/CD62eþ/CD146þ cells (mature activated CECs) and CD45/
CD62eþ/CD133þ (activated EPCs). (D,E) MECs and EPCs in healthy subjects.
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Here we demonstrated an increase of EPCs in peripheral
blood of HTLV-I carriers in comparison with healthy indi-
viduals. To our knowledge, the angiogenesis features in
asymptomatic HTLV-I carriers were not previously studied,
and it was studied only in patients with cancer, where thereTable 1. EPC numbers in cells/mm3 in HTLV1 carriers and healthy
subjects
Groups Median Minimum Maximal pa
HTLV-I carriers 0.8288 0.0920 3.3176 0.035
Healthy subjects 0.4905 0.0000 1.5660
EPC, endothelial progenitor cell.
aMann-Whitney nonparametric test for independent samples.were high numbers of EPCs and MECs (8,10,11). However,
it may be very important to study the number of EPCs in
ATLL patients to confirm our results. In this trial we used
flow cytometry to detect EPCs andMECs, although the exact
phenotype of these cells remains controversial (12).
However, our data suggest that recruitment of EPCs may
play a role in angiogenesis in HTLV-I carriers. As VEGF
is the main inductor of EPCs mobilization, our results are
in agreement with the literature because it was shown that
both VEGF and b-VEGF are increased in ATLL (7). The
tax viral protein of the HTLV-I transformed T-cell can
activate the VEGF gene and other pro-angiogenic factors
that facilitate the adhesion process between endothelial cells
and HTLV-I infected lymphocytes (13). Likewise, it is
known that HTLV1-transformed lymphocytes have higher
endothelial adhesive capacity than nontransformed
37Endothelial Cells in HTLV-I Carrierslymphocytes and develop communicating junctions with
endothelial cells (6). Nevertheless, it is unknown whether
the same characteristic is present in HTLV-I-infected
lymphocytes with no malignant transformation. This effect
was described in other viral infections such as in cytomega-
lovirus (CMV) infection. CMVpromotes vascular injury and
modulates VEGF gene expression and, consequently, stimu-
lates VEGF secretion in acute infection (14). As in ATLL, we
have both infected cells and tumor cells and in HTLV-I
carriers we have only infected cells. Analyses of these
patients are important to add knowledge concerning angio-
genesis in ATLL. According to our results, we may argue
whether increase of angiogenesis in ATLL is associated with
the neoplastic cell or is a consequence of the viral action.
Our study has some limitations. We did not measure
VEGF plasma levels in HTLV-I carriers, but our results allow
us to hypothesize that HTLV-I carriers may have high levels
of angiogenic factors. However, this hypothesis remains as
an open question and needs to be proven in studies with
a larger number of patients. Indeed, to clarify whether angio-
genesis increase inATLL is caused by leukemic cell or by the
virus or both, studies to investigate VEGF and EPC levels in
ATLL in comparison to HTLV-I carriers need to be per-
formed. Finally, if angiogenesis in ATLL is secondary to
neoplastic cell stimuli, EPC levels should be studied in the
future as a new predictive marker for disease progression.
In conclusion we showed higher levels of EPCs in
HTLV-I carriers in comparison to healthy subjects.
However, our results should be confirmed and validated
by other authors.References
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